Carfilzomib is a selective proteasome inhibitor. This Phase I study is evaluating the safety of Carfilzomib in patients with advanced solid tumors or hematological malignancies and varying degrees of hepatic impairment. It is administered on days 1, 2, 8, 9, 15, and 16 during a 28 day cycle.
Crizotinib is orally bioavailable ALK and c-MET/HGFR receptor tyrosine kinases inhibitor. This Phase I study evaluates the effect of hepatic impairment on the pharmacokinetics and safety of Crizotinib in advanced cancer patients with solid tumors.
Dasatinib is an oral tyrosine kinase inhibitor of SRC family, BCR-ABL, c-kit, EPHA2 and PDGFß receptors. It is administered in advanced cancer patients with varying levels of liver dysfunction.
Halaven is a synthetic analogue of the marine spong natural product halichondrinB. As an inhibitor of microtubules it blocks the cell division and leads to apoptosis of the cancer cells. In this study Halaven is administered on days 1 and 8 of a 21 day cycle in patients with solid tumors who also have impaired renal function.
TKI258 is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, FGFR, PDGFR, CST1R, c-KIT, RET, TrkA and FLT3. It is expected to inhibit cellular proliferation and inducing cancer cell apoptosis. TKI258 is administered orally in patients with impaired liver function.